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Strengths and limitations of this study
 ► This is the first published study to identify the rel-
ative impact of factors contributing to non- timely 
access to palliative medicines/drugs.
 ► This paper is the first in the UK to examine per-
spectives of different healthcare professionals on 
factors supporting and hindering access to palliative 
medicines/drugs.
 ► The study is also novel in its examination of cus-
tomer experience of accessing palliative medicines/
drugs and the survey achieved a high response rate.
 ► The study is possibly limited by the low number 
of sites but adds value to the literature in terms of 
barriers that need to be considered if more timely 
access to palliative medicines/drugs is to be more 
widely implemented.
AbStrACt
Objective To investigate timely access to palliative 
medicines/drugs (PMs) from community pharmacies to 
inform palliative care service delivery.
Design Mixed methods in two sequential phases: (1) 
prospective audit of prescriptions and concurrent survey 
of patients/representatives collecting PMs from pharmacy 
and (2) interviews with community pharmacists (CPs) and 
other healthcare professionals (HCPs).
Setting Five community pharmacies in Sheffield, UK and 
HCPs that deliver palliative care in that community.
Participants Phase 1: five CPs: two providing access to 
PMs within a locally commissioned service (LCS) and three 
not in the LCS; 55 patients/representatives who completed 
the survey when accessing PMs and phase 2: 16 HCPs, 
including five phase 1 CPs, were interviewed.
results The prescription audit collected information on 
75 prescriptions (75 patients) with 271 individual PMs; 
55 patients/representatives (73%) completed the survey. 
Patients/representatives reported 73% of PMs were 
needed urgently. In 80% of cases, patients/representatives 
received all PMs on the first pharmacy visit. One in five 
had to travel to more than one pharmacy to access PMs. 
The range of PMs stocked by pharmacies was the key 
facilitating factor. CPs reported practical issues causing 
difficulty keeping PMs in stock and playing a reactive 
role with palliative prescriptions. Confidentiality concerns 
were cited by other HCPs who were reluctant to share 
key patient information proactively with pharmacy teams. 
Inadequate information transfer, lack of CP integration into 
the care of palliative patients and poor HCP knowledge 
of which pharmacies stock PMs meant patients and their 
families were not always able to access PMs promptly.
Conclusions Consistent routine information transfer and 
integration of pharmacy teams in the care of palliative 
patients are needed to achieve timely access to PMs. 
Commissioners of PM access schemes should review and 
monitor access. HCPs need to be routinely made aware 
and reminded about the service and its locations.
IntrODuCtIOn
Palliative care is a holistic approach that 
seeks to improve the quality of life of 
patients with life- limiting or life- threatening 
illnesses.1 Population ageing together with 
an increase in those dying with cancer and 
non- communicable diseases will increase the 
need for palliative care at the end of life2 with 
predictions suggesting end- of- life care provi-
sion in the community and care homes needs 
to double by 2040.3 While the phrase ‘end of 
life’ is not precisely defined, it is commonly 
used in UK policy and professional guidance 
to refer to the final year of life.4 Nevertheless, 
for many people, end- of- life care will encom-
pass a much shorter timescale and timely 
access to medicines for pain and symptom 
management, which are referred to in this 
study as palliative medicines/drugs (PMs), 
will be a crucial aspect of palliative care 
service delivery.4
For most patients in primary care, the 
source of medicines is from their commu-
nity pharmacy (retail pharmacy or ‘chemist 
shop’); however, previous research and 
service audits show access to medicines such 
as injectable medicines used for symptom 
control in palliative care towards the end 
of life may not be as timely as patients and 
their families may need and wish.5–9 Phar-
macies cannot stock every possible PM; local 
formularies, which provide lists of preferred 
medicines to support symptom manage-
ment towards the end of life, help address 
this in the UK.7 8 However, knowledge on 
which PMs are listed in the formulary and 
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box 1 Overview of study phases
Phase 1
 ► Audit of palliative prescriptions meeting inclusion criteria in partici-
pating pharmacies from May to October 2016.
 ► Customer survey for those collecting palliative prescriptions in par-
ticipating pharmacies from May to October 2016.
Phase 2
 ► Semistructured face- to- face interviews with pharmacists partici-
pating in phase 1 and other healthcare professionals involved in pal-
liative care in the community from September 2016 to March 2017.
those pharmacies holding stocks may be lacking among 
prescribers,7 8 which could lead to prescriptions being 
issued for ‘non- formulary’ items not on the local list and/
or prescriptions being presented to pharmacies that do 
not routinely hold PMs.5–12 Delays may also be caused by 
legal errors on controlled drug (CD) prescriptions that 
do not comply with UK government legislation necessi-
tating the pharmacist making professional and ethical 
judgements in supporting patient care especially in the 
out- of- hours period.5 7 8 There is a suggestion that hand-
written prescriptions may be particularly problematic due 
to higher prescription error rate and out- of- hours presen-
tation7 13 14 and they are still in use in the UK for home 
visits.5 7 14
Australian research on a proposed core set of PMs 
found that pharmacies stocked on average three out of 
the list of 12,11 while a system analysis in Ireland found 
that not stocking PMs in the pharmacy was the most likely 
factor leading to delays10 and this has also been found 
in the UK.5 7 8 12 Reported contributory factors include: 
the unpredictable nature of PM prescription requests; 
national stock shortages; the prescription of PMs or 
strengths not on the recommended list; unlicensed medi-
cines; errors on CD prescriptions and the inability to 
contact the prescriber, for instance, outside general prac-
titioner (GP) (family doctor) practice opening hours.5 8 14
Community pharmacies may take part in local or nation-
ally commissioned services to support access to PMs in the 
community. In England, a locally commissioned service 
(LCS) can be provided by the local clinical commis-
sioning group (CCG) or a local enhanced service (LES) 
can be commissioned by National Health Service (NHS) 
England Area Teams in response to public need.15 Such 
services differ across geographical regions and are not 
commissioned from all pharmacies, causing confusion 
for patients and their caregivers who are often involved 
in prescription collection and medicines management 
when a patient’s condition deteriorates.9 16–18 Further-
more, a lack of monitoring of PM availability against those 
prescribed both within the pharmacy and by the commis-
sioning body could mean PMs are not available when 
needed. (Aslett, M. and Wall- Hayes, L. 2015. ‘Access to 
palliative drugs—community pharmacy scheme—audit.’ 
Unpublished NHS audit report, Birmingham, UK).
There is little research internationally on community 
pharmacists’ (CPs) involvement in supporting timely 
access to PMs. Hence, this study seeks to answer the 
question ‘What barriers are encountered by community 
pharmacists in delivering timely access to palliative care 
medicines.’ Due to the dearth of published research 
particularly in the context of community pharmacy 
services in England, the aim of this study was to evaluate 
timely access to PMs in the community pharmacy setting 
and make recommendations to inform the commis-
sioning of services and future practice. The objectives 
were to:
 ► Determine the timeliness of access to PMs in the 
community.
 ► Investigate the prevalence and nature of prescribing 
errors on prescriptions for PMs presented to commu-
nity pharmacies and determine whether errors impact 
on access to urgent PMs.
 ► Investigate processes for accessing PMs from pharma-
cies where an LCS operates including referrals when 
PMs are not available.
 ► Explore the views and experiences of CPs and other 
stakeholders on accessing PMs from community 
pharmacies.
MethODS
This study used mixed methods across two sequential 
phases (see box 1 for study overview) conducted in Shef-
field, UK.
Phase 1: Audit of PM supplies over 6- month data collec-
tion period. Sheffield pharmacies were recruited through 
e- bulletin sent by the Local Pharmaceutical Committee, 
fax invitation to LCS PM pharmacies (19 of the 128 in 
the city), and verbal invitation at a local pharmacy prac-
tice development event. CPs expressing interest in taking 
part were given an information leaflet and consent form 
via email providing further information and the study 
inclusion criteria. Eligible CPs participated in the LCS 
or usually dispensed 30 or more PM prescriptions in a 
month based on NHS digital prescription data for opioid 
analgesics and midazolam dispensed in pharmacies in the 
region.19 Exclusion criteria were: (1) pharmacists who 
had worked in the UK for less than 12 months (to ensure 
participants were familiar with UK and local community 
pharmacy services) and (2) if the company or manager 
did not give permission for participation. None of the 
interested pharmacies had to be excluded based on these 
criteria.
A pragmatic approach to sample size was taken; the 
intention was to recruit up to 15 pharmacies; however, 
only five CPs consented to participate, partly due to the 
unexpectedly low level of PM prescriptions reported. 
Informed consent was obtained. EJM personally visited 
each participating pharmacy to brief them on the 
project, data collection forms and answer any questions 
to enhance consistency of data collection.
Consenting pharmacies collected data on 30 consec-
utively presented prescriptions, which contained medi-
cines likely to be prescribed for palliative care patients 
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using criteria developed by EJM. Eligible prescriptions 
were for adults aged 18 years or over and included one or 
more of the following: a long- acting oral or transdermal 
strong opioid coprescribed with a short- acting opioid; fast- 
acting fentanyl product; prescription of subcutaneous or 
syringe pump PMs, specified unlicensed medicines used 
in palliative care, as well as any prescription issued by the 
palliative care team. Prescription data were collected for 
6 months between May and October 2016. Pharmacy data 
collection forms were developed by EJM and reviewed by 
JDM and piloted in one community pharmacy. The form 
recorded anonymised prescription data including: names 
of medications on the prescription; whether there was a 
legal or non- legal error on a CD prescription and further 
information on how that error was resolved including 
whether the patient’s summary care record (SCR) 
was accessed to resolve an error. Legal and non- legal 
prescription errors were identified by the CPs and non- 
legal errors were classified by EJM according to criteria 
within the PRACtICe study.20 Further details on non- legal 
errors were completed on a separate form to allow EJM to 
verify the classification. Previous research suggested that 
delays may be caused by doctors prescribing products not 
on the community pharmacy PM list7 8 (eg, midazolam 
5 mg/5 mL prescribed when midazolam 10 mg/2 mL 
on list) hence where prescribers issued legally correct 
prescriptions for products not recommended on the LCS 
PM list these were classified as non- legal errors. Subcuta-
neous items in the audit were checked by EJM against the 
LCS list to identify non- formulary items in both LCS and 
non- LCS pharmacies.
Prescriptions were classified as urgent when (1) the 
survey respondent stated it was urgent, (2) they included 
anticipatory subcutaneous medicines and/or PMs to be 
given by a syringe pump or (3) they were from an out- 
of- hours provider. The date/time a prescription was 
received by the pharmacy and the date/time when it was 
ready for collection were recorded by pharmacy staff.
Survey of patients/representatives collecting PM 
prescriptions. The national pharmacy contracting 
organisation the Pharmaceutical Services Negotiating 
Committee Community Pharmacy Patient Question-
naire21 was used as a basis to develop a short customer 
survey of experiences of patients and their representatives 
of collecting PM prescriptions from the community phar-
macy. Questions included the perceived urgency of the 
prescription, the customer’s previous use of the pharmacy, 
whether they were the patient or the patient’s represen-
tative, whether they were able to access all required PMs, 
whether they had been referred to the pharmacy (eg, by 
another healthcare professional (HCP)) and whether 
they had to visit more than one pharmacy to access the 
PMs on the prescription. When patients/representatives 
indicated that not all items were available they were given 
the option of completing a free- text section to explain 
how they intended to get these items. A free- text section 
allowed respondents to record their answer to ‘are there 
any things that could have been improved to make your 
visit better?’ The customer survey was developed by EJM 
with input from JDM, AB, a hospice service user coordi-
nator and risk manager. It was piloted in one pharmacy, 
further refined and piloted with patients within a hospice 
day centre. Pharmacy teams were provided with a written 
briefing on how to introduce the survey to patients/
representatives. Individuals collecting prescriptions for 
PMs were invited to participate by pharmacy support staff 
or the CP depending on the pharmacy. A unique number 
was used to match the customer survey to the pharmacy 
data form to allow verification of the data and assess any 
discrepancies. Patients/representatives not attending the 
pharmacy, for example, home deliveries and care home 
residents, did not complete the customer survey.
Phase 2: Semistructured interviews with CPs and 
other HCPs involved in care of palliative patients. EJM 
conducted interviews with the five CPs participating 
in phase 1 and with a purposive sample of other HCPs 
involved in palliative care in the community including 
GPs, community specialist palliative care team, commu-
nity nurses, district nurses and intermediate care team 
members. HCPs were invited to participate via e- bul-
letin, email and through gatekeepers (practice managers 
and team leaders). Interviews were audio recorded with 
consent and transcribed verbatim by EJM. The interviews 
explored views and experiences of accessing PMs in the 
community; factors that supported or hindered access 
and their knowledge of the LCS. The interview schedule 
is available on request from the authors.
Data analysis
Prescription data were entered into and analysed using 
IBM SPSS V.23 statistical software by EJM. Frequencies 
and percentages were calculated for all categorical vari-
ables with mean and SD calculated for time to process 
prescriptions. Crosstabs was used to check relationship 
between legal or clinical errors and prescription gener-
ation method.
Interview transcripts were read by EJM for content 
familiarisation then annotated and coded manually using 
a priori themes from the study objectives. Following 
development of an analytical framework, two over- 
arching themes were then used to ‘chart’ the coded data: 
(1) timely access to PMs, (2) the CP’s role in palliative 
care, using the Framework Method.22 The framework was 
revised and iteratively refined with CW and AB against 
the coded interview transcripts with emergent themes 
and subthemes applied across the whole data set. Summa-
ries of data were added within the framework to capture 
participants’ views. Mapping and interpretation of find-
ings compared similarities and contrasts between and 
across professional groups and was supported through 
discussion and reflection with AB and CW.
Data from both phases were then triangulated where 
two or more sources agreed or contrasted with each 
other to help explain the quantitative results of the study. 
Triangulation enhanced the validity and reliability of 
the results and enabled integration of the findings, such 
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Table 1 Prevalence of medication problems
Type of medication problem Frequency of problem Total no of prescription items Percentage prevalence
Legal errors 3 271 1.1
Prescribing errors (see table 2) 8 271 3.0
Out of stock with supplier 1 271 0.4
Non- formulary LCS item requested 12 135 8.9
LCS, locally commissioned service.
Table 2 Prescribing errors (n=271)
Type of prescribing error Frequency
Percentage 
prevalence
Incomplete information on 
prescription
2 0.7
Dose/strength error 2 0.7
Generic/brand error 2 0.7
Allergy* 1 0.4
Quantity error 1 0.4
*Allergy ascertained from patient or patient’s medical record on 
pharmacy dispensing system.
that it was possible to make recommendations for prac-
tice improvement and identify issues for service commis-
sioners to consider.
Patient involvement
The study was informed by research priorities in pallia-
tive care23 and through EJM’s professional experience 
including discussion with patients and carers experi-
encing medicines access problems following admission to 
a hospice. The customer survey tool was developed and 
piloted with patients in a hospice setting.
reSultS
Participants in each phase of the study
Phase 1 CP audit: Participating pharmacies were diverse 
in that they included pharmacies classified as indepen-
dent (having fewer than five branches) and multiple 
(having five or more branches); two provided access to 
PMs under an LCS and three did not. Pharmacy sites were 
a combination of high street/local parade of shops (3) 
and suburban (2) with both suburban pharmacies colo-
cated with a GP practice. For pharmacies not consenting 
to take part, the main reason cited was small numbers of 
palliative care prescriptions dispensed in the pharmacy.
Customer survey: Customer surveys were completed 
against 55/75 CP audit forms; response rate 73.3%. Non- 
completion related primarily to home deliveries and care 
home prescriptions.
Phase 2 CP and other HCP Interviews: 16 individ-
uals participated: CPs (5), GPs (3), specialist palliative 
care team (2), community nurses (5) and intermediate 
care team (1). The five CPs were also involved in phase 
1. Median interview durations were 51 min for CPs and 
18.5 min for GPs and other HCPs.
Phase 1: prescription characteristics
A total of 271 prescription items on 75 prescription 
forms was recorded (range 2–33 per pharmacy, median 
14) over the 6- month audit period with a mean number 
of 3.6 prescription items per form. This included 68.3% 
(n=185) of PMs identified as urgent, 49.8% (n=135) 
containing subcutaneously administered PMs and 24.7% 
(n=67) containing subcutaneously administered CDs. In 
91.1% (n=123) of cases, subcutaneous items were chosen 
from the LCS formulary list. Non- formulary choices were 
either different presentations of formulary items (5.9%, 
n=8) or items not on the LCS list (3.0%, n=4). Varying 
strengths of midazolam ampoules accounted for 41.7% 
(n=5) of non- formulary choices.
Prescriptions were computer generated (n=245, 90.4%) 
or handwritten (n=22, 8.1%), with no prescriptions deliv-
ered electronically via the electronic prescription service 
(EPS); missing data (n=4, 1.5%). Most prescriptions were 
written by NHS GPs providing in- hours services (n=233, 
86%), with out- of- hours GPs (n=33, 12.2%) or specialist 
palliative care team (n=5, 1.8%) writing the remainder. 
There were no non- medical prescriber prescriptions 
within the sample. Prescriptions were presented to the 
pharmacy during GP opening hours (from 9:00 to 18:00 
hours, Monday to Friday) (n=176, 64.9%) or outside GP 
hours (evenings and weekends) (n=77, 28.4%); missing 
data on 6.6% of forms (n=18).
Phase 1: prescription audit
Legal errors were present in 1.1% (n=3) of prescrip-
tion items; all of which were computer generated, not 
specifying a dose on a CD given via infusion. There were 
no legal errors on handwritten prescriptions. There 
was insufficient evidence of a difference between the 
prescription generation method and legal errors (Fish-
er’s exact two- sided test, p=0.052). Other non- legal 
prescribing errors, such as incomplete information, 
dose/ strength error, generic/ brand error, allergy and 
quantity error, occurred in 3.0% (n=8) of items. Table 1 
summarises the prevalence of different medication 
problems on prescriptions and table 2 indicates types of 
prescribing errors using categories as in the PRACtlCe 
study.20
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Figure 1 Time taken to access urgent palliative medicines from community pharmacies . LCS, locally commissioned service.
Phase 1: time to access urgent palliative care medicines
Valid time data were available for 57.8% (n=107) of 185 
urgent items (n=73 missing data; n=5 excluded where 
PMs unavailable and prescription taken elsewhere and 
recorded as 0 min). Median time to process urgent PMs 
(time of prescription receipt to time of complete supply 
of PMs) was 2 hours (10 min in LCS pharmacies and 
5 hours in non- LCS pharmacies). The maximum time to 
process urgent PMs was 3 hours and 39 min within LCS 
pharmacies, and 47 hours and 15 min within non- LCS 
pharmacies (see figure 1).
The median time taken to access urgent medications 
(n=107) between pharmacies participating in the LCS 
and pharmacies not participating in the service was 
significantly different (independent samples median test 
p=0.002 at 95% confidence level); with pharmacies not 
participating in the LCS taking significantly longer than 
pharmacies in the LCS.
Legal errors had minimal effect on access as all urgent 
PMs with legal errors were available within 30 min of 
presentation. Legal errors were resolved by: contacting 
the nursing home to specify the dose to be given on a 
prescription for PMs via a syringe pump using a commu-
nity medicines administration record, using the phar-
macy patient medication record to access information 
on a previously issued prescription, and contacting the 
prescriber. The patient’s SCR was not used to resolve 
errors in the prescription audit sample.
Phase 1: customer survey
Survey responses showed that representatives collected 
PMs on behalf of the patient (65.5%); for both themselves 
and the patient (1.8%); and patients collected their own 
PMs (32.7%); 72.9% of surveys overall indicating the 
prescription included urgent item(s). All cases for urgent 
subcutaneous medications were collected by a representa-
tive on behalf of a patient. In 42.6% of cases, the patient/
representative attended their usual pharmacy. Patients/
representatives also indicated the pharmacy was: conve-
nient (14.8%); one of several pharmacies used (20.4%), 
or that they had been referred to the pharmacy for the 
medications (21.8%).
In 80% of cases, patients/representatives received all 
medications against the prescription at the first pharmacy 
they visited. In 20% (11/55), one or more items on the 
prescription was not available, in five of these, the item(s) 
were urgent. Free- text sections were completed for 6 of 
the 11 cases of unavailable items. Four indicated that they 
would return to collect the item from the pharmacy and 
two said they would try another pharmacy to obtain the 
items.
Thirteen respondents made additional comments 
on whether their experience could have been better. 
Comments were mostly positive: six indicated ‘no’, 
‘none’, ‘no fine’ or similar phrase; five made comments 
on the staff or service: ‘friendly services under difficult 
circumstances’, ‘no—staff really friendly and helpful, 
service was quick and efficient’, ‘nothing—excellent and 
quick service’ and one explained ‘nothing much that 
would make it better, but I phone in advance to make 
sure my items are in stock’. One respondent requested to 
‘keep a stock of all required items’.
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Overall one in five patients/representatives had to go 
to more than one pharmacy to get urgently needed PMs, 
increasing to one in three for urgent subcutaneous injec-
tion prescription items. One in every two patients/repre-
sentatives referred to the pharmacy by another HCP had 
to go to more than one pharmacy. Data from the prescrip-
tion audit and customer survey were triangulated to verify 
the validity of the information in phase 1.
Phase 2: interview findings
Findings from the interviews are presented in four 
sections: timely access, challenges, knowledge of LCS, 
and communication and collaboration. The findings are 
illustrated by verbatim quotes from the interviews where 
appropriate.
timely access
Anticipating need and forward planning were key themes 
to ensure timely access to PMs.
… I could go in now and say, ‘I need these drugs’ 
(and the CP might say) ‘Oh I can get them in for 11 
o’clock tomorrow morning’ [exasperated laugh] it’s 
like that’s not really very helpful, I need them now 
(HCP7, Community Healthcare Professional)
Community nurses and palliative care team staff reported 
strategies to enhance access including conducting an end 
of week check and balance for those on syringe pumps to 
ensure sufficient stock for over the weekend when fewer 
staff were available. Specialist palliative care team staff also 
described making do with the medicines already available 
in the house and then ordering medication for the next 
day. CPs perceived that patients/HCPs phoning ahead for 
large quantities would be helpful. Insufficient quantities 
of PMs could adversely impact patient symptom manage-
ment and had consequences for staff resources, however, 
not all situations could be taken into consideration.
… a GP won’t prescribe a syringe driver ahead of 
time…we are always…having to do it now not in a 
more considered way (HCP4, Community Healthcare 
Professional)
… I remember having to go [to the pharmacy] 
in the middle of doing a [syringe] driver because 
there weren’t enough drugs (HCP8, Community 
Healthcare Professional)
The local CCG had implemented a template on the GP 
prescribing system to provide a ‘suite’ of PMs according 
to local last days of life algorithms, which included some 
of the injectable medicines listed on the LCS formulary. 
Even so, in phase 1 several ‘non- formulary’ medications 
not on the local CCG PM list were prescribed and in phase 
2 CPs in LCS pharmacies described non- compliance with 
the local formulary as a reason for a lack of timely access 
to PMs.
We’ve got three different strengths of oxycodone in-
jection, and they [GPs] prescribe all three, and you 
might not have one, you might have the other…it’s 
just so frustrating… (P4, Community Pharmacist)
The big problem is midazolam…so many strengths…
volumes of ampoules…the GPs just pick one. (P5, 
community pharmacist)
Challenges
CPs described practical issues in supplying PMs, for 
example, stock ordering processes including: timing 
of deliveries and the inability to return CD items to 
suppliers due to legal restrictions; CD cabinet size (to 
meet UK legal requirements for storage) and quantities 
on prescriptions.
We don’t have an ability to be able to keep a lot [con-
trolled drugs] and so we have a particular issue with 
the quantities that they write on the prescriptions 
sometimes which can impact on the next patient (P4, 
Community Pharmacist)
We’ve only got very small CD cabinets…the more 
controlled drugs you keep the more issues you are 
going to have (P1, community pharmacist)
Furthermore, patient records and charts to check 
opioid dose changes and syringe pumps were often not 
accessible to CPs.
With regards to changing doses or monitoring, I think 
that would be difficult for a community pharmacist. 
We have the summary care [record]… with palliative 
care the dose can change, you’ve got the pink card…
sometimes we see [the pink card] and sometimes we 
don’t (P2, Community Pharmacist)
… they [CPs] don’t get the pink card [syringe pump 
chart] they simply get the prescription (HCP3, GP)
I might only need…extra diamorphine…whereas I 
might be using midazolam and haloperidol…but I’ve 
still got a supply of those, so they [CPs] don’t always 
know what’s in the [syringe] driver (HCP4, Commu-
nity Healthcare Professional)
Knowledge of lCS
HCPs had little knowledge of either the LCS or the phar-
macies commissioned to provide it but knew which phar-
macies were likely to keep some PMs in stock.
I don’t know who’s commissioned we just basically 
know which ones we go to that are more likely to have 
it. (HCP4, Community Healthcare Professional)
… relatives who are running right left and centre 
trying to get hold of these meds…there is a com-
missioned service…but we don’t know who they are. 
(HCP1, Community Healthcare Professional)
GPs generally thought that all pharmacies kept some 
injectable PMs in stock but said they might ring in advance 
to check the medication was available if a supply was 
needed urgently. Non- LCS pharmacist providers knew of 
the service and how to refer a patient/carer if they did 
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not have the requested medication available. Usually, 
they would phone ahead to the pharmacy to check the 
medication was available before making a referral. Being 
able to make a referral depended on whether the carer 
had access to a car.
… if they haven’t got a car it’s sometimes a bit tricky 
(P1, Community Pharmacist)
Communication and collaboration
Participants described strategies to enhance access to 
PMs. Two non- LCS pharmacies had worked with GP prac-
tices to discuss and agree to stock a subset of the LCS PMs; 
they had similar response times to pharmacies in the LCS.
… we went to them[GPs] and said, what are the most 
common drugs you would prescribe in palliative 
care…they [GPs] came back with a list…so we would 
try to keep the stock in for what they specified (P3, 
Community Pharmacist)
CPs reported that some patients/carers contacted the 
pharmacy when they ordered a prescription for a CD that 
might not be stocked. Community and specialist pallia-
tive care team staff described how they would suggest the 
pharmacist kept sufficient stock when they had someone 
on a syringe pump or large quantities of injectable medi-
cations. There appeared to be some examples where 
excellent communication and collaboration existed 
between GPs, HCPs and CPs, which resulted in more 
timely access for PMs.
… one GP…rang us and said well what have you got 
in stock and what can you get, which I found really, 
really useful because as the prescription came in the 
stock came in and this thing was completely seamless 
(P3, Community Pharmacist)
When we were down at [previous community nurse 
location] …there was a pharmacy next door so…if 
we had any quick questions, we would go and talk to 
them…they were more like part of the team (HCP7, 
Community Healthcare Professional)
However, concerns around patient confidentiality by 
GPs and other HCPs meant that more often this informa-
tion was not shared with the pharmacy team in advance of 
receiving the prescription.
… but you’re limited by what you can tell them [phar-
macists] obviously from a confidentiality point of 
view… (HCP11, Community Healthcare Professional)
We don’t communicate with them [community phar-
macist] what the problem with the patient is we just 
prescribe the drugs… sometimes they can obviously 
work it out. (HCP3, GP)
I do have some slight reservations about them [phar-
macists] knowing all those ins and outs…I’m not 
sure how wide that circle is in there [pharmacy]…I’d 
prefer it …on just a case by case basis…to an identi-
fied clinician… (HCP10, GP)
DISCuSSIOn
The sequential use of mixed methods to first quantify 
the ‘problem’ and then qualitative methods to provide 
context to the barriers to timely supply of PMs generated 
new insights into a long- standing problem. Timeliness 
of access was found to primarily relate to a mismatch 
between medicines stocks held by CPs and the PMs that 
GPs prescribed. Legal errors on CD prescriptions played 
a much smaller role and had little impact on access to 
PMs in this study. Stock availability as a significant factor 
to support timely access has also been seen in previous 
studies.5 8 10 11
Study results appear to indicate a low prevalence of legal 
errors on palliative care prescriptions considering 42% of 
prescriptions were for CDs. Previous studies suggest that 
legal errors on prescriptions can range from less than 1% 
up to approximately 1.9%14 20 24–28 though data do not 
specifically focus on palliative care prescriptions. Legal 
errors in the current study arose on computer generated 
prescriptions for CDs administered by a syringe pump. 
The primary care organisation prescribing template 
for PMs may have impacted positively, minimising the 
number of legal errors.
Our findings of differential time to access PMs between 
community pharmacies participating in the LCS for PMs 
and non- participants indicate that a local service can 
enhance access. Those pharmacies working with local GP 
practices to keep a small agreed range of PMs in stock had 
similar access times to those within the LCS, suggesting 
that such collaboration can also support more timely 
access and improve patient and carer experience. Such 
wider collaboration has been advocated within national 
policy drivers and enables greater integration of phar-
macy teams in improving patient care.29–32 Some HCPs 
considered CPs ‘part of the team’ but others saw them 
only in their ‘supply’ role. Together with concerns about 
confidentiality, this prevented many HCPs from commu-
nicating with CPs about available stock or giving advance 
warning to allow stock to be obtained in a more timely way. 
A particular concern seemed to be who else, in addition 
to the pharmacist, might have access to sensitive infor-
mation. Commissioners could remind primary care staff 
of community pharmacy ethical and information gover-
nance practices to correct any misunderstandings. They 
could also encourage HCPs to be proactive in checking 
stock availability with the patient’s usual pharmacy.
Palliative patients often rely on family members and 
friends to support them with managing their medica-
tion especially towards the end of life.9 16–18 Our findings 
show that some families obtain urgently required medi-
cines from a pharmacy different than the one that usually 
supplied the patient’s medicines. It is unclear what effect 
these changes in continuity of care between pharmacies 
might have towards the end of life, but this study shows 
that some CPs enhance access by calling other pharma-
cies to ascertain they have PMs in stock. A potential solu-
tion could be through CPs having read and write access 
to the SCR allowing them, whether they are the patient’s 
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regular, out of hours or LCS pharmacy, to record patient 
care scenarios to ensure safe, continuity of care of PMs. 
Variable accessibility and difficulties in use of SCR by CPs33 
may suggest wider access to patient records is required.
One in five patients/representatives accessing PMs had 
to go to more than one pharmacy. This is the first study 
to quantify the number of patients/representatives who 
had to do so, with associated inconvenience, wasted time 
and stress. This finding could be explained by a lack of 
awareness of the LCS since this is not advertised to the 
public and there was also low awareness among HCPs and 
GPs in the interviews. Monitoring of LCS/LES services 
by commissioners may not always be effective. One audit 
found only 1 of 19 pharmacies held all PMs on the formu-
lary list and some CPs were not aware that the scheme 
was active. (Aslett, M. and Wall- Hayes, L. 2015. ‘Access to 
palliative drugs—community pharmacy scheme—audit’ 
Unpublished NHS audit report, Birmingham, UK). 
There was also evidence in phase 1 of prescriptions being 
written for items not on the LCS list, which would not 
usually be stocked in the pharmacies. Commissioners’ 
service audits could investigate referral patterns from 
pharmacies not within the LCS, furthermore monitoring 
of LCS pharmacies may improve practice and caregivers’ 
experience. Commissioners could also act to improve 
awareness of LCS among local HCPs.
Some limitations affect the interpretation/generalis-
ability of the findings of this study. The small sample of 
participating pharmacies, missing data, reliance on CPs 
to identify prescriptions and confounding factors such as 
time of day, number and type of staff working in the phar-
macy may limit interpretation of the results and introduce 
a degree of bias. Differences in the commissioning of 
access to PMs within England also may limit the findings 
as there is no standard service specification stating the 
outcomes to be measured. Furthermore, the geographical 
restriction with data only collected in one city could limit 
application to other areas including those in remote loca-
tions, with different out- of- hours providers, and access to 
palliative care support in the community. Nevertheless, 
the study adds value to the literature in terms of barriers 
that need to be considered if more timely access to PMs is 
to be more widely implemented and the methodology has 
enabled new insights into factors contributing to timely 
access.
COnCluSIOn
The findings of this study suggest that legal prescribing 
errors may now have a smaller impact on access to 
urgent PMs from community pharmacies compared 
with mismatches between stock availability and PMs 
prescribed. Both participation in an LCS or collaboration 
with local prescribers are likely to improve access to PMs.
recommendations for future commissioning and practice
Commissioners should
1. Encourage GP practices to work with local pharmacies 
to keep a small range of PMs available.
2. Remind HCPs of the ethical and information gover-
nance requirements of community pharmacies and en-
courage early contact to check stock availability.
3. Involve patients and the public in designing audits of 
LCS.
Community pharmacies should improve their commu-
nication with HCPs around pharmacy opening times and 
cut- off times for same- day delivery of medicines.
Moving forward, NHS England will be supporting 
development and integration of CP services into primary 
care through its Pharmacy Integration Fund34 and this 
may also improve interprofessional communication and 
access to PMs.
Patient Involvement
The design of the study was based on EM’s experience as 
a clinical pharmacist including discussions with patients 
and their families on accessing medicines. The research 
question was, therefore, derived from patients’ and family 
carers’ experience on accessing medicines towards the 
end of life. A Hospice Service User Coordinator provided 
support with the customer survey based on their expe-
rience of conducting surveys. Furthermore, patients 
within a hospice day centre supported the piloting of the 
customer survey.
Correction notice This article has been corrected since it was published. The title 
and Table 2 are updated.
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